A once daily drug combination of sofosbuvir-velpatasvir for 12 weeks resulted in sustained eradication of several genotypes of the hepatitis C virus in 99% of patients in a clinical trial, according to a study in The New England Journal of Medicine. Read more and read the study abstract.
© 2020 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder